Ceralasertib
- Generic Name
- Ceralasertib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N6O2S
- CAS Number
- 1352226-88-0
- Unique Ingredient Identifier
- 85RE35306Z
- Background
Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).
ESMO 2024: Novel Approaches in Personalized Medicine and AI Highlighted
• The PIONeeR trial explored novel immunotherapy combinations to overcome resistance to PD-1/PD-L1 inhibitors in advanced NSCLC, but did not meet its primary endpoint of improved disease control.
• The Rome trial demonstrated that genomic-guided therapy significantly improved objective response rate and progression-free survival in pretreated patients with metastatic solid tumors.
• Prov-GigaPath, a novel AI foundation model, shows promise in predicting genomic alterations and analyzing the tumor microenvironment from pathology slides, enhancing personalized medicine.
UCLA Researchers Pioneer Organoid Platform for Personalized Sarcoma Treatment
• UCLA researchers have developed a platform using patient-derived organoids to model sarcoma tumors, addressing the lack of personalized treatment options.
• The platform successfully created organoids from 114 sarcoma samples, maintaining key characteristics of the original tumors for drug screening.
• High-throughput drug screening identified potentially effective FDA-approved treatments for 59% of specimens, showing promise for personalized medicine.
• A clinical trial (PREMOST) is underway to validate the platform's predictive power in osteosarcoma patients, potentially broadening drug use for rare cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath